Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 704243
                    [Title] => Annual zoledronic acid dose reduces back pain disability
                    [Summary] => 
A yearly dose of zoledronic acid significantly reduced the number of days of disability because of back pain in older women with osteoporotic fractures, based on data from the HORIZON Pivotal fracture study.
                    [DatePublished] => 2011-07-10 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 651365
                    [Title] => Data show osteoporosis drug preserves bone mass, provides fracture protection
                    [Summary] => 
Novartis announced recently that new six-year data reinforce the long-term efficacy and safety profile of once-yearly zoledronic acid 5 mg in postmenopausal women with osteoporosis.
                    [DatePublished] => 2011-01-27 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 559564
                    [Title] => Zoledronic acid an option for osteoporotic men
                    [Summary] => 
The Food and Drug Admi-nistration’s recent approval of yearly zoledronic acid infusions for the treatment of low bone mass in men with osteoporosis will give clinicians a treatment option for men other than oral weekly therapy.
                    [DatePublished] => 2010-03-21 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [3] => Array
                (
                    [ArticleID] => 482522
                    [Title] => Novartis offers 1-year insurance for patients on osteoporosis drug
                    [Summary] => 
Novartis has launched a one-of-its-kind free one-year fracture insurance program for patients receiving the research-based pharmaceutical company’s breakthrough once-yearly osteoporosis drug.
                    [DatePublished] => 2009-07-02 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

ZOLEDRONIC

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 704243
                    [Title] => Annual zoledronic acid dose reduces back pain disability
                    [Summary] => 
A yearly dose of zoledronic acid significantly reduced the number of days of disability because of back pain in older women with osteoporotic fractures, based on data from the HORIZON Pivotal fracture study.
                    [DatePublished] => 2011-07-10 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 651365
                    [Title] => Data show osteoporosis drug preserves bone mass, provides fracture protection
                    [Summary] => 
Novartis announced recently that new six-year data reinforce the long-term efficacy and safety profile of once-yearly zoledronic acid 5 mg in postmenopausal women with osteoporosis.
                    [DatePublished] => 2011-01-27 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 559564
                    [Title] => Zoledronic acid an option for osteoporotic men
                    [Summary] => 
The Food and Drug Admi-nistration’s recent approval of yearly zoledronic acid infusions for the treatment of low bone mass in men with osteoporosis will give clinicians a treatment option for men other than oral weekly therapy.
                    [DatePublished] => 2010-03-21 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [3] => Array
                (
                    [ArticleID] => 482522
                    [Title] => Novartis offers 1-year insurance for patients on osteoporosis drug
                    [Summary] => 
Novartis has launched a one-of-its-kind free one-year fracture insurance program for patients receiving the research-based pharmaceutical company’s breakthrough once-yearly osteoporosis drug.
                    [DatePublished] => 2009-07-02 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

Annual zoledronic acid dose reduces back pain disability

By YOUR DOSE OF MEDICINE | By Charles C. Chante MD | July 10, 2011 - 12:00am

A yearly dose of zoledronic acid significantly reduced the number of days of disability because of back pain in older women with osteoporotic fractures, based on data from the HORIZON Pivotal fracture study.

Opinion

Data show osteoporosis drug preserves bone mass, provides fracture protection

January 27, 2011 - 12:00am

Novartis announced recently that new six-year data reinforce the long-term efficacy and safety profile of once-yearly zoledronic acid 5 mg in postmenopausal women with osteoporosis.

Science and Environment

Zoledronic acid an option for osteoporotic men

By YOUR DOSE OF MEDICINE | By Charles C. Chante MD | March 21, 2010 - 12:00am

The Food and Drug Admi-nistration’s recent approval of yearly zoledronic acid infusions for the treatment of low bone mass in men with osteoporosis will give clinicians a treatment option for men other than...

Opinion

Novartis offers 1-year insurance for patients on osteoporosis drug

July 2, 2009 - 12:00am

Novartis has launched a one-of-its-kind free one-year fracture insurance program for patients receiving the research-based pharmaceutical company’s breakthrough once-yearly osteoporosis drug.

Science and Environment